Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors
**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and destruction that leads to severe disability. There are no clear guidelines regarding the order of therapies. Gathering data on treatment patterns outside of a cli...
Saved in:
Main Authors: | Xue Han, Francis Lobo, Michael S. Broder, Eunice Chang, Sarah N. Gibbs, David J. Ridley, Irina Yermilov |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2021-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2021.23684 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
by: Kei Ikeda, et al.
Published: (2013-01-01) -
Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept
by: Ting Wang, et al.
Published: (2025-01-01) -
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
by: Peter Youssef, et al.
Published: (2025-01-01) -
Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison
by: Ulf Lindström, et al.
Published: (2025-01-01) -
The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis
by: Alberto Floris, et al.
Published: (2025-01-01)